Umecrinecognition.jpg

Umecrine Cognition – Phase I clinical trial initiated

Umecrine Cognition – Phase I clinical trial initiated

Umecrine Cognition has raised new funds to support clinical development of novel drug candidate for hepatic encephalopathy. The new funds will be used by Umecrine Cognition to conduct a Phase I (first in human) clinical trial with the company’s oral drug candidate GR3027 in 58 healthy volunteers to assess safety, tolerability, and pharmacokinetics, and to establish clinical proof-of-principle with regard to the mechanism of action.

For further information, please visit company home page
http://www.umecrinecognition.com


Text by: Göran Lidgren

Published: 12 June, 2016



Share article:

Text by:

Published:

Facebook

Göran Lidgren

12 June, 2016